Surrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...
Read moreOptimising evidence generation in trial design, while navigating regulatory and local payer requirem...
Read moreNegotiations between the Trump administration and pharmaceutical companies on lowering U.S...
Read moreAdvanced Therapy Medicinal Products (ATMPs) are offering transformative, and often life-saving, trea...
Read moreAdvanced Therapy Medicinal Products (ATMPs) are leading in healthcare innovation, providing potentia...
Read moreThe pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t...
Read moreIn 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p...
Read moreFive success pillars — your JCA evidence-generation checklist From 12th January 2025, the Eu...
Read moreA €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such ...
Read moreProving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf...
Read more